Couple things I don't remember from the 10k, although I might be wrong, but not sure what they entail.
On January 19, 2022, the Company issued a work order (the “Work Order”) to Cyprotex US, LLC (“Cyprotex”), pursuant to which Cyrprotex will perform certain drug interaction services for the Company for an aggregate fee of $165,455. The Work Order is governed by the Cyprotex’s Standard Terms and Conditions for Discovery Services dated August 2, 2021. The Company incurred approximately $9,000 for this Work Order.
On January 31, 2022, the Company entered into a Statement of Work (the “SOW”) with Charles River Laboratories, Inc. (“Charles River”). The Statement of Work is subject to the General Terms and Conditions of Charles River. Pursuant to the SOW, Charles River will conduct a certain pre-clinical animal study (the “Study”) relating to Bryostatin-1 pharmacodynamics and drug distribution, for an initial aggregate fee of $197,600. The Company may terminate the Study without cause upon 30 days prior written notice.
Only other comment is we still have 30.5 million in the bank with 6-7 months until AD results. FragileX trial will only cost 700k. MS we don't know.
News 
Market Data 
Discover 
